Mirtazapine Ratiopharm (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2, 5‑HT3 and histamine H1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirtazapine Ratiopharm is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its receptor profile. It often causes more sedation and weight gain but may be preferred when patients experience insomnia or need an appetite stimulant. Choice of therapy depends on individual patient factors and side‑effect tolerability.

Mirtazapine Ratiopharm tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use after the expiry date.

The tablets are taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include agranulocytosis, severe neutropenia, hepatic dysfunction, seizures, and the potential for suicidal thoughts, especially when therapy is initiated or dosage is changed. Patients should be monitored closely for any of these events.

Mirtazapine is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) within 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. It should be used with caution in patients with cardiovascular disease, low blood pressure, or a history of seizures.